Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate

[Image: see text] The fungal-derived Taiwanese natural product antroquinonol A has attracted both academic and commercial interest due to its reported exciting biological properties. This reduced quinone is currently in phase II trials (USA and Taiwan) for the treatment of non-small-cell lung carcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Villaume, Matthew T., Sella, Eran, Saul, Garrett, Borzilleri, Robert M., Fargnoli, Joseph, Johnston, Kathy A., Zhang, Haiying, Fereshteh, Mark P., Dhar, T. G. Murali, Baran, Phil S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827469/
https://www.ncbi.nlm.nih.gov/pubmed/27163023
http://dx.doi.org/10.1021/acscentsci.5b00345
_version_ 1782426466242265088
author Villaume, Matthew T.
Sella, Eran
Saul, Garrett
Borzilleri, Robert M.
Fargnoli, Joseph
Johnston, Kathy A.
Zhang, Haiying
Fereshteh, Mark P.
Dhar, T. G. Murali
Baran, Phil S.
author_facet Villaume, Matthew T.
Sella, Eran
Saul, Garrett
Borzilleri, Robert M.
Fargnoli, Joseph
Johnston, Kathy A.
Zhang, Haiying
Fereshteh, Mark P.
Dhar, T. G. Murali
Baran, Phil S.
author_sort Villaume, Matthew T.
collection PubMed
description [Image: see text] The fungal-derived Taiwanese natural product antroquinonol A has attracted both academic and commercial interest due to its reported exciting biological properties. This reduced quinone is currently in phase II trials (USA and Taiwan) for the treatment of non-small-cell lung carcinoma (NSCLC) and was recently granted orphan drug status by the FDA for the treatment of pancreatic cancer and acute myeloid leukemia. Pending successful completion of human clinical trials, antroquinonol is expected to be commercialized under the trade name Hocena. A synthesis-enabled biological re-examination of this promising natural product, however, reveals minimal in vitro and in vivo antitumor activity in preclinical models.
format Online
Article
Text
id pubmed-4827469
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-48274692016-05-09 Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate Villaume, Matthew T. Sella, Eran Saul, Garrett Borzilleri, Robert M. Fargnoli, Joseph Johnston, Kathy A. Zhang, Haiying Fereshteh, Mark P. Dhar, T. G. Murali Baran, Phil S. ACS Cent Sci [Image: see text] The fungal-derived Taiwanese natural product antroquinonol A has attracted both academic and commercial interest due to its reported exciting biological properties. This reduced quinone is currently in phase II trials (USA and Taiwan) for the treatment of non-small-cell lung carcinoma (NSCLC) and was recently granted orphan drug status by the FDA for the treatment of pancreatic cancer and acute myeloid leukemia. Pending successful completion of human clinical trials, antroquinonol is expected to be commercialized under the trade name Hocena. A synthesis-enabled biological re-examination of this promising natural product, however, reveals minimal in vitro and in vivo antitumor activity in preclinical models. American Chemical Society 2015-12-23 2016-01-27 /pmc/articles/PMC4827469/ /pubmed/27163023 http://dx.doi.org/10.1021/acscentsci.5b00345 Text en Copyright © 2015 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Villaume, Matthew T.
Sella, Eran
Saul, Garrett
Borzilleri, Robert M.
Fargnoli, Joseph
Johnston, Kathy A.
Zhang, Haiying
Fereshteh, Mark P.
Dhar, T. G. Murali
Baran, Phil S.
Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
title Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
title_full Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
title_fullStr Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
title_full_unstemmed Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
title_short Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
title_sort antroquinonol a: scalable synthesis and preclinical biology of a phase 2 drug candidate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827469/
https://www.ncbi.nlm.nih.gov/pubmed/27163023
http://dx.doi.org/10.1021/acscentsci.5b00345
work_keys_str_mv AT villaumematthewt antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT sellaeran antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT saulgarrett antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT borzillerirobertm antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT fargnolijoseph antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT johnstonkathya antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT zhanghaiying antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT fereshtehmarkp antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT dhartgmurali antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate
AT baranphils antroquinonolascalablesynthesisandpreclinicalbiologyofaphase2drugcandidate

Ejemplares similares